Literature DB >> 1733189

The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism.

J C Konje1, E O Otolorin, O A Ladipo.   

Abstract

Blood glucose and plasma insulin levels during an oral glucose tolerance test were measured in 20 women using continuous subdermal levonorgestrel (Norplant) for contraception over a 12-month period. Changes in carbohydrate metabolism occurred as early as 1 month but were most marked after 6 months. After 1 month the area under the glucose and insulin curves increased by 12.3% and 37.7%, respectively. This increase was more marked by 6 months, but by 12 months it was significantly less marked. Although changes in the blood glucose and plasma insulin levels at different times during the oral glucose tolerance test occurred, they were all within normal limits for normal women. The peak blood glucose and insulin levels after insertion of the implant occurred 60 minutes after the glucose load, as opposed to 30 minutes before insertion. Apart from this, there was a significant delay in the return of these levels to fasting values. We conclude that this product, like any other progesterone-containing contraceptive, alters carbohydrate metabolism, but these alterations are not clinically significant in normal women. It is, however, possible that in potential cases of diabetes it may predispose to frank diabetes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733189     DOI: 10.1016/0002-9378(92)91819-v

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

Review 1.  New concepts in diabetes mellitus. I: Treatment, pregnancy and aetiology.

Authors:  R Taylor; M Vanderpump
Journal:  Postgrad Med J       Date:  1994-06       Impact factor: 2.401

2.  Insulin resistance and development of diabetes mellitus associated with megestrol acetate therapy.

Authors:  P Jain; L S Girardi; L Sherman; M Berelowicz; L G Smith
Journal:  Postgrad Med J       Date:  1996-06       Impact factor: 2.401

Review 3.  Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.

Authors:  A J Coukell; J A Balfour
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 4.  Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.

Authors:  Irving Sivin
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.